Adding Benlysta (belimumab) to standard therapy increased the percentage of people with active lupus nephritis who experienced improved renal function in a Phase 3 trial. The BLISS-LN study (NCT01639339) was designed to evaluate Benlysta’s safety and efficacy in people with active lupus nephritis, a common and…
News
Physical and emotional abuse during childhood may increase the risk of developing systemic lupus erythematosus (SLE) later in life, a new study has found. The study, “Association of Childhood Abuse with Incident Systemic Lupus Erythematosus in Adulthood in a Longitudinal Cohort of Women,” was published in …
The U.S. Food and Drug Administration (FDA) has granted fast track designation to itolizumab as a potential therapy for lupus nephritis, a common and serious complication of systemic lupus erythematosus (SLE) that can lead to kidney failure. This designation is given to compounds that show considerable potential in treating serious conditions for which…
Fatigue has a major impact on quality of life in people with systemic lupus erythematosus, and measuring it using a patient-reported tool may prove useful in clinical trials, new research shows. The findings were presented at the recent 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting…
This year’s Lupus Research Alliance (LRA) Breaking Through Gala, billed as the world’s largest single lupus fundraising event, took in $3 million for research into the autoimmune disorder. Some 600 members of the global lupus community turned out for the Nov. 25 New York City affair that celebrates…
Treatment with an investigational antibody therapy known as BIIB059 was well-tolerated and decreased disease activity in people with cutaneous lupus erythematosus (CLE) — lupus affecting the skin — with or without systemic lupus erythematosus (SLE), which affects other organs and systems, top-line results of a Phase 2 study…
Adding the experimental oral therapy voclosporin to standard-of-care treatment is safe and nearly doubles the proportion of complete kidney responses in people with lupus nephritis, according to top-line data from a Phase 3 study. Aurinia Pharmaceuticals, the company developing voclosporin, hopes to make the treatment available to…
Adding RC18 (telitacicept) to standard therapy significantly lowered disease activity in systemic lupus erythematosus (SLE) patients in a Phase 2b trial, data show. The treatment was also well-tolerated. Researchers at RemeGen, the company developing RC18, presented the findings, “A Human Recombinant Fusion Protein Targeting B…
The Lupus Foundation of America (LFA) marked the 10th year of its Evening of Hope Gala by honoring leaders in the fight against lupus while raising funds to advance the nonprofit’s mission. Hundreds of advocates and community members gathered in New York City to recognize the efforts…
Oral treatment with cenerimod shows promising safety and efficacy in people with mild to moderate systemic lupus erythematosus (SLE), including reduced disease activity and lower levels of immune cells in the blood, according to data from a Phase 2 trial. The research, “First Use of Cenerimod, a Selective…
Recent Posts
- To my ‘forever nurse,’ who finally gave me my diagnosis of lupus
- New analyses show Benlysta may aid flare control, kidney health
- Can art therapy help lupus patients improve cognitive function?
- With chronic illness, checking in means asking, ‘How ya really doin’?’
- FDA approves Gazyva as lupus nephritis treatment